The biggest private biotech investments in April 2024
This issue of our newsletter is supported by Wacker Chemie.
It’s fair to say that April 2024 was a good month for private biotech fundraising.
In fact, it was actually the best month of the year so far, both in terms of the number of rounds and the total amount raised.
Overall, there were 35 rounds and companies around the globe managed to raise $3.1 billion.
Xaira Therapeutics’ came out on top of the pack after raising an incredible $1 billion in a private equity round.
But who else managed to raise big?
To find out more, read the full article: “The biggest private biotech investments in April 2024”
A MESSAGE FROM OUR SPONSOR WACKER CHEMIE
Engage The Experts For Novel pDNA, mRNA, AND LNP Formulations & Manufacturing
WackerBiotech is your CDMO partner for advanced therapies, offering the production ofpDNA, mRNA, LNPs and fill and finish. We are a highly engaged team with decadesof CDMO experience you can trust. Global facilities with integrated pDNA, mRNAand LNP capabilities support our robust nucleic acid services.
🔥 More noteworthy articles from this week:
Pulmonary hypertension - which can lead to severe health complications, including heart failure - is a challenging disease and has historically been treated through symptom management. But the biotech industry is now working hard to develop more effective treatments for the condition.
Bruton tyrosine kinase (BTK) inhibitors are a class of drugs that were initially developed to control the spread of cancer and were first approved over a decade ago to treat a rare blood cancer. Now, they are in the running to treat a host of autoimmune diseases too.
When it comes to getting your dream job in biotech, it is important to prepare for the interview process in advance so that you know exactly what to expect going into it. Here, we spoke to two industry experts to give their advice on how candidates can best prepare for an interview at a biotech company.
Currently, the most commonly prescribed type of medication used to treat depression are serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs). However, these can sometimes be ineffective. That’s why, in the last few years, the biotech industry has started to come up with new, faster-acting antidepressants.
Belgium has a thriving biotech and life science sector, with more than 300 biopharmaceutical companies operating in the country. It is positioned as Europe’s second-largest biotech industry, and is renowned for its expertise in pharmaceuticals, diagnostics, and medical technology. Here we take a look at six biotechs based in Belgium.
This week, we have a conversation with the CEO of Cytokinetics, Robert Blum, about the company’s heart drug pipeline, including aficamten, its next-in-class cardiac myosin inhibitor, which has seen great results from a pivotal phase 3 clinical trial in obstructive hypertrophic cardiomyopathy.
Cell avidity is a measure of binding probability between T cells and tumor cells, and can be used to identify CAR-T products that are both potent and safe. This is useful, as there is a urgent need of new and innovative methods to streamline the assessment of potential toxicities early in the development process, ensuring safer and more effective treatments.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.
Scientific & Medical Communication • I help scientific companies explain their technology to multiple audiences • 16 years of experience • PhD in Medicinal Chemistry • Bilingual in French and English
3mo16 companies out of this list of 20 are US-based, 2 are Chinese and only 2 are European... not surprising I guess but I was hoping for more European-based biotechs in there.
Founder of the #CreativeDisruption & #AgileLeaders Forums & #BiotechBuddies and #CoffeeBuddies Events
3moAn interesting read about the latest private investment trends, giving reasons for optimism!